Trial Profile

A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of Ipatasertib (GDC-0068) in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipatasertib (Primary) ; Docetaxel; Enzalutamide; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Genentech

22 Dec 2020 Status changed from active, no longer recruiting to completed.
03 Jun 2020 Planned End Date changed from 1 Jan 2020 to 1 Sep 2020.
03 Jun 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Sep 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com